Genincode PLC (LON:GENI)
0.95p+5.56%
Spriggl Score: Moderate— sign in to explore; full breakdown with Premium
Last 30 trading days
Spriggl AI Verdict
“Clinical validation boosts US prospects, yet widening losses and cash burn threaten survival before FDA approval.”
Sign up free to read the full investment thesis, bull case, bear case and what to watch.
About Genincode PLC
GENinCode Plc engages in the development and commercialization of clinical genetic tests for predictive analysis of risk to a patient's health based on genes in the United Kingdom, Spain, Italy, the United States, Germany, and internationally. The company offers CARDIO inCode Sco…
- Sector:
- Healthcare
- Industry:
- Diagnostics & Research
- Market Cap:
- £6.6M
Recent dividends
No recent dividends recorded.
Get the full Spriggl analysis — free
A free Spriggl account gets you the screener, a watchlist, AI verdicts and a free full report every day — across Genincode PLC and 1,500+ UK and US stocks. The full score breakdown and AI analysis come with Premium.
Start free